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Background: Once daily intravenous aminoglycoside dosing (ODD) is widely used to treat acute Pseudomonas aeruginosa exacerbations in
patients with cystic fibrosis. Controversy exists as to what is the most appropriate method of therapeutic drug monitoring (TDM) of such
therapy with recommendations including trough plasma concentrations of <1 mg/L or <2 mg/L, area under curve (AUC) and various
nomograms. This study aimed to compare the exposures to ODD of tobramycin in adults and children with cystic fibrosis using the AUC and
trough TDM approaches.
Methods: Using a mono-exponential software program to calculate AUC from 2 plasma concentrations, AUCs were determined in 22 adults
with pre-dose tobramycin concentrations <1 mg/L. The exposure of 5 children with reduced tobramycin clearances was simulated at the
usual recommended dose of 10 mg/kg/daily but retaining a trough <1 mg/L.
Results: A tobramycin dose of 10 mg/kg of tobramycin in these patients with normal serum creatinine and a trough concentration <1 mg/L
resulted in exposures in excess of those associated with conventional 8-hourly dosing.
Conclusions: The TDM approach of a trough <1 mg/L, as used with conventional 8-hourly tobramycin dosing, is not relevant to ODD.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Area under curve; Pharmacokinetics; Pharmacodynamics1. Introduction
Intravenous aminoglycosides are widely used for the
treatment of acute respiratory exacerbations in patients with
cystic fibrosis (CF) who are infected with Pseudomonas☆ Presented at the Eighteenth Annual North American Cystic Fibrosis
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1569-1993/$ - see front matter © 2006 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.05.015aeruginosa (PA). Several studies have demonstrated that
once daily dosing (ODD) has similar efficacy to conven-
tional multiple daily dosing in children and adults with cystic
fibrosis (CF) and with the potential benefit of less
nephrotoxicity [1–3].
Variations exist in the method of therapeutic drug
monitoring (TDM) with many centres relying on trough
(pre-dose) levels to minimise toxicity. A number of
approaches have been advocated including trough or pre-
dose plasma concentrations of <0.5 or <1 or <2 mg/L,
area under the plasma concentration–time curve (AUC)
and various nomograms utilising population based/
Bayesian pharmacokinetics [4–7]. A recent consensused by Elsevier B.V. All rights reserved.
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Trust recommended that a trough level of tobramycin of
<1 mg/L should be adopted for drug monitoring as used
in the TOPIC study [3]. However trough levels should
be interpreted with caution as a level of <1 mg/L may
not exclude toxicity [8]. Given the potential for
nephrotoxicity with repeat aminoglycoside treatment, it
is imperative that a TDM methodology which minimises
potential risk is used [9]. The AUC approach sets target
AUCs for ODD that are equivalent to those seen with
the “peak and trough” approach used with conventional
8-hourly dosing, ie. aims for equivalent “exposures”
[5,10,11].
The aim of this study was to compare the exposures to
tobramycin of adult and paediatric CF patients using two
TDM methodologies: the AUC approach and the trough
concentration of <1 mg/L approach.
2. Methods
2.1. Study subjects
Two groups of patients were studied. Data on tobramycin
levels following ODD drug administration in adult patients
with CF were collected from a prospective study at the Leeds
adult CF Unit. Paediatric data were obtained retrospectively
from the Adelaide Women's and Children Hospital's TDM
database. Data was collected in compliance with guidelines
of both Ethical Committees.
2.2. Adult population
Bloods for tobramycin assay were collected prospec-
tively in patients admitted with a respiratory exacerbation
to the Leeds CF Unit and enrolled in a ODD efficacy
study [2]. Exclusion criteria were age less than 16 years,
the presence of an elevated serum creatinine or a past
history of tobramycin hypersensitivity. Subjects received
10 mg/kg once daily of tobramycin as an infusion over
1 h for a total of 2 weeks in combination with a second
intravenous antipseudomonal antibiotic. No patients were
prescribed colistin in combination with tobramycin due
to the risk of potentiating nephrotoxicity. Three bloods
for plasma tobramycin concentrations were collected
approximately 1 h and 6–9 h after end of 3rd infusion,
and prior to the 4th dose (i.e. in the same dosing
interval). The pre-dose concentration had to be <1 mg/L
for the patients to be enrolled in this study. Seven of the
22 patients were studied on two occasions a week apart
with the dose remaining unchanged since troughs were
<1 mg/L. Plasma tobramycin concentrations were
determined by immunoassay using the Abbott AxSym
(Abbott Laboratories, Maidenhead, UK). The AUC for
each serial measurement of tobramycin was calculated
after completion of the study using the method described
below.2.3. Paediatric population
Children with CF attending the Adelaide Women's and
Children's Hospital with acute PA respiratory exacerbations
are routinely prescribed tobramycin therapy initiated at a
once daily dose of 10 mg/kg given over 15 min. The dose is
subsequently adjusted to the target AUC calculated from two
plasma tobramycin levels collected at least 1 h and
approximately 6 h after the start of the infusion.
Children with impaired tobramycin clearance were
identified by searching the TDM database for individuals
who had required doses of less than or equal to 7 mg/kg once
daily of intravenous tobramycin to achieve our target AUC
of 100 mg h/L [10,11]. Pharmacokinetic data was then re-
calculated assuming that patients had been given a standard
starting dose of 10 mg/kg. Data were also generated for a
hypothetical patient given 10 mg/kg, with 1 h concentrations
of 30 mg/L or 20 mg/L and trough (23.5 h) concentrations
ranging from 1.2 to 0.2 mg/L.
2.4. Pharmacokinetic analysis
The AUC was determined from the 2 plasma concen-
trations taken at 1 h and between 6 and 9 h after a dose.
The data were entered into the Aminoglycoside Levels
And Daily Dose Indicator program (ALADDIN) which we
have used for some 7–8 years [12]. This program uses one
compartment, mono-exponential pharmacokinetics to cal-
culate AUC and the “virtual peak” plasma concentration
by extrapolating the plasma concentration–time line back
to time zero. In addition to these two key parameters
which optimise aminoglycoside pharmacodynamics, the
program computes volume of distribution, elimination
half-life, total clearance, calculated minimum (trough)
concentration and recommended dose to achieve the target
AUC. Pharmacokinetic data obtained by using ALADDIN
has been previously shown to be more accurate than
methods which rely on the use of either a single concen-
tration to determine AUC or utilisation of a nomogram
[13].
3. Results
3.1. Adult population
A total of 22 adult patients with mean age 24 years (range
18–31) were enrolled. Seven of the 22 subjects had serial
tobramycin levels measured on 2 occasions a week apart
(shown as A and B). All patients had a measured trough
concentration of <1 mg/L. Individual estimated pharmaco-
kinetic data are shown in Table 1.
Pharmacokinetic analysis using the computer program
was performed on 29 occasions following ODD of
tobramycin. On twenty-one (21) occasions in 15 patients,
the dose of 10 mg/kg resulted in tobramycin AUCs which
exceeded the target of 100 mg h/L [5,10]. In these patients,
Table 1
Patient and pharmacokinetic data for adult patients
Patient Age,
years
Dose,
mg
Dose,
mg/kg
t1/2, h Vd,
L/kg
Cl,
mL/min/kg
AUC,
mg h/L
Adjusted
dose
Dose change (%)
for AUC=100
1 22 580 9.9 2.1 0.22 1.2 138 420 −28
2 31 800 8.1 4.0 0.20 0.6 232 340 −59
3A 23 490 9.1 1.8 0.19 1.2 126 390 −20
3B 490 9.1 1.9 0.21 1.3 120 410 −16
4A 22 480 9.1 1.4 0.13 1.1 142 340 −29
4B 480 9.1 1.5 0.12 0.9 167 290 −35
5A 23 550 9.5 1.8 0.20 1.3 125 440 −20
5B 550 9.5 1.6 0.18 1.3 125 440 −20
6 18 440 9.9 1.6 0.17 1.3 142 310 −30
7A 20 440 10 2.1 0.20 1.1 151 290 −34
7B 440 10 1.8 0.18 1.2 148 300 −32
8 19 660 10 2.1 0.17 0.9 178 370 −44
9 22 500 9.9 1.9 0.20 1.2 138 360 −28
10A 27 580 9.9 3.3 0.28 1.0 172 340 −41
10B 520 10 2.4 0.24 1.1 150 350 −33
11 23 500 10.3 3.2 0.20 0.7 238 210 −58
12 22 340 7.8 1.7 0.26 1.8 72 470 +38
13 31 560 10 3.3 0.32 1.1 152 370 −34
14 21 520 10 1.7 0.30 2.0 85 610 +17
15 23 400 9.9 2.2 0.29 1.6 105 380 −5
16A 23 440 9.5 1.9 0.30 1.8 87 510 +16
16B 440 9.5 1.5 0.19 1.5 108 410 −7
17A 26 640 9.8 1.9 0.31 1.8 89 720 +12
17B 640 9.8 2.1 0.34 1.9 87 740 +16
18 27 560 10.7 2.3 0.23 1.2 154 360 −36
19 26 560 9.7 1.5 0.27 2.1 80 710 +27
20 28 600 9.6 1.3 0.25 2.1 75 800 +33
21 23 550 10 2.0 0.26 1.5 111 490 −11
22 31 500 9.8 1.3 0.27 2.3 72 700 +40
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recommended by the program. If relatively minor dose
reductions (<15%) are ignored (as is done in our clinical
practice), there would still be 13 patients receiving doses
which gave an exposure to tobramycin that was, on average,
35% greater than the recommended target AUC. Patients 2, 8
and 11 had AUCs of the order of twice the target.
Pharmacokinetic estimates generated by the computer
program identified 3 patients (2, 11, 13) where the calculated
24 h trough concentration of tobramycin was 0.6, 0.3 and
0.2 mg/L respectively, suggesting impaired clearance. All
other patients had an estimated minimum concentration of
zero. By contrast, 4 patients (12, 19, 20, 22) required a dose
increase of 27–40%. Relevant data to attempt to correlate
these 2 TDM approaches with clinical efficacy or toxicity
were not part of the study design.Table 2
Patient and pharmacokinetic data for paediatric patients
Patient Wt, kg Age,
years
Dose,
mg
Dose,
mg/kg
Virtual peak,
mg/L
1 41 15 200 4.9 24
2 42 12 280 6.7 30
3 72 17 420 5.9 32
4 38 11 220 5.8 26
5 55 17 380 6.9 303.2. Paediatric population
Table 2 shows data for the most recent admissions for 5
paediatric patients who had received previous courses of IV
tobramycin and fulfilled our selection criteria. All of these
patients had serum creatinine values within the normal range.
The simulated virtual peak and trough concentrations, if
these patients had been given 10 mg/kg, are shown in Table
3: all of these patients would have recorded a measured
trough concentration of <1 mg/L, but with AUCs ranging
from 144 to 223 mg h/L.
Data for a hypothetical patient given 10 mg/kg, with 1 h
plasma tobramycin concentrations of either 30 mg/L or
20 mg/L and a range of pre-dose concentrations are reported
in Table 4. Although 6 of the 8 trough concentrations would
have met a TDM criterion of <1 mg/L, the AUCs in all butt1/2, h Vd,
L/kg
Cl,
mL/min/kg
AUC,
mg h/L
Calculated
trough, mg/L
3.2 0.21 0.7 109 0.1
2.3 0.22 1.1 101 <0.1
2.5 0.19 0.9 115 <0.1
2.2 0.22 1.1 84 <0.1
2.3 0.23 1.2 99 <0.1
Table 4
Simulated data: tobramycin 10 mg/kg
Conc,
mg/L 1 h
Conc,
mg/L 23.5 h
Virtual
peak,
mg/L
t1/2, h Vd,
L/kg
Cl,
mL/min/kg
AUC,
mg h/L
30 1.2 34.6 4.8 0.29 0.7 234
30 0.8 35.2 4.3 0.28 0.8 214
30 0.4 36.3 3.6 0.28 0.9 188
30 0.2 38.7 2.7 0.26 1.1 152
20 1.2 22.7 5.5 0.44 0.9 172
20 0.8 23.1 4.8 0.43 1.0 156
20 0.4 23.8 4.0 0.42 1.2 135
20 0.2 25.3 2.9 0.40 1.6 107
Table 3
Simulated pharmacokinetic data for paediatric patients at 10 mg/kg
Patient Dose, mg Virtual peak,
mg/L
AUC,
mg h/L
Calculated trough,
mg/L
1 410 48 223 0.26
2 420 45 152 0.03
3 720 53 197 0.07
4 380 45 144 0.02
5 550 43 143 0.03
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factor of 1.5–2.3.
4. Discussion
Once daily dosing of tobramycin in patients with CF has
been studied by a number of groups [1–3,14,15]. Although
patient numbers are lacking compared to studies of non-CF
patients, the observations are similar—at least equal efficacy
and perhaps reduced nephrotoxicity when compared to
conventional MDD.
Appropriate therapeutic drug monitoring of aminoglyco-
side therapy contributes to efficacy and reduces the risk of
toxicity. Patients with CF may now expect to live into at least
the fourth decade and may receive numerous courses of these
potentially toxic antimicrobial agents. Progressive renal
toxicity following repeated courses of tobramycin has been
demonstrated in such patients [9]. It is thus essential to
optimise the clinical toxicity monitoring (e.g. auditory and
renal function) as well as the TDM of these patients.
Although the evidence to support ODD of tobramycin in
CF has accumulated, little attention has been paid to the most
appropriate method of TDM. The various approaches to such
monitoring have been the topic of two symposia of the
International Association of Therapeutic Drug Monitoring
and Clinical Toxicology [16]. Methods of TDM include
single plasma concentration at 6–14 h after a dose and
comparison to a nomogram; “individualisation” using 2
samples and guidelines that cater for the type of infection; a
pharmacokinetic–pharmacodynamic model and other nomo-
grams [13,16]. However, many of these programs may not be
suitable for patients with CF since the nomograms are often
based on data from non-CF adults with normal renal
function.
Paterson evaluated 3 AUC methods of monitoring serum
aminoglycoside levels [13]. In addition to ALADDIN, two
methods using nomograms and AUC determinations requir-
ing a single level were evaluated. When comparing the 3
methods, at least 25% of the dosage recommendations
differed by 80 mg or more. When only patients who
developed nephrotoxicity were considered, 28.6% of the
doses recommended by ALADDIN and a nomogram
differed by more than 80 mg. In all but 2/35 doses,
ALADDIN recommended a lower dose.
Various nomograms have been adopted for TDM of ODD
and have the attraction of only requiring a single sample.However most nomograms do not allow for the significant
variations in pharmacokinetics seen in patients with cystic
fibrosis, burns, pregnancy, intensive care and young age—
TDM methodologies such as individualised AUC provide
such flexibility. Nomograms result in inaccurate dosing and
should be abandoned in favour of individualised dosing [17].
The use of trough (pre-dose) plasma level monitoring
continues to be commonly employed as the TDMmethod for
ODD of aminoglycosides. The United Kingdom Cystic
Fibrosis Trust has recently recommended that a trough level
should be measured and a pre-dose tobramycin concentra-
tion of <1 mg/L be accepted as per the TOPIC study [3]. The
assumption is that a pre-dose concentration of this order
suggests a reduced risk of toxicity. This is an inappropriate
conclusion. In the presence of a 50% reduction in tobramycin
renal clearance, equivalent to an elimination half-life of the
order of 4 h in patients with CF, a dose giving a peak of the
order of 30 mg/L with ODD will still result in a 24 h trough
of <1 mg/L. However the “exposure” to tobramycin as
measured by AUC will be significantly above a target of
100 mg h/L [10,11]. Reductions in clearance of this order
will not necessarily be reflected by an increased serum
creatinine, particularly in patients with CF [9]. Al-Aloul et al.
found a high prevalence of abnormal renal function in CF
patients treated with repeated courses of tobramycin yet all
patients had blood urea and creatinine values within normal
ranges [9].
Aminoglycoside toxicity has been associated with 2
parameters—the trough plasma concentration and the
duration of treatment [18,19]. As argued by Barclay, the
combination of these 2 parameters is a measure of total drug
exposure which is represented pharmacokinetically by AUC
[7]. Trough concentrations of <1 mg/L can still result in
exposures significantly greater than those associated with
conventional multiple daily dosing [5]. Extrapolation to a
trough concentration of <2 mg/L from MDD to ODD places
the patient at even greater risk of nephrotoxicity [7].
It is generally believed that aminoglycosides are well
tolerated in patients with CF. However the potential to
produce nephrotoxicity is inherent in these agents and
prolonged exposure due to increased survival may be a
complicating factor [9]. The suggestion of reduced
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AUC [20]. The probability of nephrotoxicity increases as the
daily exposure, as indexed by the AUC, increases [20].
Murry demonstrated an increased incidence of nephrotoxi-
city in patients with greater cumulative AUCs, length of
aminoglycoside therapy and higher minimum plasma
concentrations [21]. The mean±S.D. minimum plasma
gentamicin or tobramycin concentration in the ODD patients
who developed nephrotoxicity was 0.45±0.53 mg/L and
1.19±0.97 mg/L in the multiple daily dosing group [21]. The
ODD group had a mean cumulative AUC of 780 mg h/L over
a mean therapy duration of 8.4 days, suggested that even a
daily AUC of 100 mg h/L has the potential to cause
nephrotoxicity. The mean daily AUC of 66±28 gave an
overall successful treatment outcome of 94% [21]. However
these patients did not have cystic fibrosis and the increased
dosage needs of such patients infected with Pseudomonas
need to be considered in defining a target AUC [22].
ALADDIN is a program designed to adjust aminoglyco-
side doses and/or dosing intervals based on achieving target
AUCs and “virtual peaks” for patients with or without CF.
These parameters were chosen because they have been
shown in human and animal studies to be the important
pharmacodynamic parameters for efficacy of aminoglyco-
sides [11]. Using 2 levels taken several hours apart in a single
dosing interval, ALADDIN calculates these parameters and
also that individual's mono-exponential pharmacokinetic
parameters. Two or three point sampling has been shown to
produce pharmacokinetic estimates that do not clinically
differ [23,24]. ALADDIN estimates the elimination rate
constant from the exponential line through the 2 points and
AUC from the integral of line (total AUC minus AUC from
24 h to affinity). Although not a compulsory field, if height is
added, then the ideal body weight is calculated based on
ideal body mass index by age. If the actual weight is more
than 25% above or below this value, then ideal body weight
is used in calculations involving weight. This compensates
for obesity and wasting which have been shown to give
misleading aminoglycoside kinetics [25]. Although other
approaches such as Bayesian may be more robust, our
confidence in ALADDIN is supported by the reproducibility
of data such as demonstrated in Table 1 for those 7 patients
who were studied on 2 occasions a week apart.
The individual's pharmacokinetic parameters of virtual
peak (extrapolation of kinetic curve back to time zero),
elimination half-life, volume of distribution, clearance,
trough level and AUC are calculated. Availability of the
individual's pharmacokinetic parameters not only provides
valuable data on renal function and dosing, but values of e.g.
Vd, t1/2 or Cl which, when significantly outside those
normally seen, may indicate errors in dose times or sampling
times as recorded on the laboratory report. This engenders a
sense of caution when interpreting computer generated dose
changes that are “outside the norm”. Accurate recording of
dose and sampling times is a potential weakness in this AUC
approach and demands appropriate education of nursing andlaboratory staff. Unexpected values for t1/2 and Cl may
identify patients with significantly impaired aminoglycoside
clearance (GFR) but in whom serum creatinine is still within
the normal range.
Samples should be taken as far apart as possible, when
distribution is complete and when plasma concentrations are
greater than the lower levels of accurate quantitation of the
assay. Given the rapid elimination in children with CF, we
have selected times of at least 1 h and approximately 6 h
post-dose. There is evidence to demonstrate a prolonged
distribution phase for aminoglycosides given once daily.
Demczar et al. demonstrated a prolonged distribution half-
life and lower clearance at 7 mg/kg of gentamicin vs 2 mg/kg
[26]. However, no such difference in distribution kinetics
was found between doses of 10 mg/kg of tobramycin vs
3.3 mg/kg in adult patients with cystic fibrosis [27].
However, both studies recommend sampling at approxi-
mately 2 h after the beginning of a 60 min infusion to ensure
that this first sample is in the post-distribution phase and to
increase the accuracy of any determinations of mono-
exponential pharmacokinetic parameters. Bates administered
doses of 7–15 mg/kg of tobramycin to CF patients as a
20 min infusion and compared the pharmacokinetic data to
those with multiple daily dosing [14]. This group concluded
that distribution with ODD was complete by 1 h after the
initiation of the 20 min infusion. ALADDIN, using mono-
exponential pharmacokinetics and an AUC based on a back-
extrapolation to time zero from a 1 h level, will not include
that portion of the AUC in the distribution phase above the
extrapolated line, ie underestimates the true AUC. On
balance, we have persisted with the first sample being taken
at 1 h and accept values within ±15% of the target AUC.
Aminoglycoside therapy will remain an integral compo-
nent of the treatment of acute respiratory exacerbations in
patients with CF. Although once thought not to be a
significant issue, toxicity from these agents may well
become so as repeated and prolonged courses result from
increased survival. In a survey of 53 UK cystic fibrosis
centres, 22 patients were identified who developed amino-
glycoside related acute renal failure over an 8 year period
[28]. Although the use of ODD appears to be one method of
reducing such toxicity, as with MDD, it is imperative that the
TDM of ODD is optimal and that we ensure the exposure of
patients to these drugs does not exceed that with MDD.
Although nomograms and trough TDM methodologies have
the attraction of a single plasma level, there is no evidence
that ODD requires less monitoring than conventional MDD
[29]. TDM which recommends a trough (pre-dose) level of
<1 mg/L is inappropriate and may place CF patients with
normal serum creatinines but decreased tobramycin clear-
ance at risk of over-exposure and greater toxicity. Con-
versely, it may also result in under-dosing. The AUC method
permits individualised dosing especially in those patient
categories such as CF with altered pharmacokinetics. Given
that AUC:MIC is the pharmacodynamic parameter with the
highest correlation with pulmonary function improvements,
130 K.P. Coulthard et al. / Journal of Cystic Fibrosis 6 (2007) 125–130then selecting AUC as the TDM methodology may not only
minimise toxicity but also optimise efficacy [30].
Although the optimal target AUC and pharmacokinetic
model of calculation require further study, this individualised
approach reduces the incidence of nephrotoxicity and
permits optimal dosing [31]. A prospective study of trough
level TDM vs AUC methodologies and employing sensitive
and early indicators of nephrotoxicity such as tubular
enzymes and proteins is urgently required.
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